Mironid CMO interview

Our Chief Medical Officer, Cass Kelleher spoke to In Vivo about her role at Mironid, the unmet medical need in ADPKD and the potential impact of our LoAc® small molecules in development for the treatment of ADPKD.

Read the full Q&A here: https://invivo.citeline.com/IV148658/Mironid-On-Reducing-The-Burden-Of-Polycystic-Kidney-Disease

The Latest

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseAugust 5, 2026
Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the [...]
Read more de Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026
At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]
Read more de Mironid Raises Awareness for PKD with 1,000 km Team Challenge
Q&A with David Henderson, Head of BiologyMarch 19, 2026
ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]
Read more de Q&A with David Henderson, Head of Biology